Neurology Central

Alzheimer’s disease: Phase III clinical trials of lanabecestat to discontinue

Eli Lilly (IN, USA) and AstraZeneca (Cambridge, UK) have announced that they are discontinuing the global Phase III clinical trials of lanabecestat, an oral β-secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease (AD).

The decision has been based on recommendations by an independent data monitoring committee (IDMC), which concluded that both the AMARANTH trial and the DAYBREAK-ALZ trial were not likely to meet their primary endpoints upon completion and therefore, should be stopped for futility.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.